Lupin, Torrent zero in on Bayer's biz

Dermatology segment of Bayer's portfolio is valued at $1 bn

Lupin, Torrent join race to buy Bayer’s derma biz
Pharmaceutical tablets and capsules
Manuel BaigorriGeorge Smith AlexanderAri AltstedterSohini Das London/Mumbai/Ahmedabad
Last Updated : Sep 28 2016 | 1:41 AM IST
Drug makers Lupin, Torrent and Cadila Healthcare are considering making bids to acquire Bayer’s dermatology business, valued $1 billion.

A Bloomberg report on Tuesday said the Indian drug companies are weighing offers with a view to grow their dermatology portfolio. Sun Pharmaceutical Industries, too, is in the race, along with top pharmaceutical companies and private equity firms.

Bayer is looking to divest its dermatology business ahead of a $66-billion acquisition of Monsato.

Dermatology is an area of focus for top drug makers in the country. Recently, Sun Pharma announced a tie-up with Almirall for development and commercialisation of a new drug to treat plaque psoriasis. For Lupin, too, dermatology is an area of focus and the company has 20 product filings in the US.

A Lupin spokesperson declined comment. Torrent Pharma spokespersons, too, were not available for comment.  

Last year, Torrent had acquired Zyg Pharma, which was a part of the Mumbai-based Emcure group. It specialises in dermatological formulations.

In January 2015, Torrent had raised close to Rs 10,000 crore by issuing securities and had said that it is open to acquisitions to fuel its growth. At the time, the company told Business Standard that funds would be used to refinance existing borrowings, as well as organic and inorganic growth.

Torrent had acquired the domestic business of Elder Pharma in December 2013, a deal which gave it access to new therapeutic areas in which it was looking to expand its presence.

Cadila Healthcare Chairman and Managing Director Pankaj Patel had, in an interview to Business Standard earlier this year, said the company is open to both product acquisitions as well as bigger acquisitions in the US market.

It has acquired the animal health business of Zoetis and some brands from Albert David earlier this year, and is making smaller acquisitions in the domestic space to plug the gaps in the therapeutic categories.

With Bloomberg inputs

DEAL STREET
  • Sun Pharma recently announced a tie-up with Almirall for development and commercialisation of a new drug
     
  • Torrent had raised close to Rs 10,000 cr and had said it is open to buyouts
     
  • Torrent had last year acquired Zyg Pharma, which was a part of the Mumbai-based Emcure group
     
  • Cadila Healthcare, earlier this year, said it was open to both product buyouts as well as bigger acquisitions in the US market
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 28 2016 | 12:50 AM IST

Next Story